Document Type

Blog Post

Publication Date

2-26-2026

Abstract

This past week, Louisiana’s Attorney General filed a lawsuit, Markezich v. FDA, challenging the distribution of medication abortion to patients without an in-person doctor’s appointment. When the Supreme Court rejected a challenge to the Food and Drug Administration’s (“FDA’s”) approval of mifepristone in 2024, it was considered a setback for the anti-abortion movement.  Markezich confronts the FDA’s approval of telehealth, and the Supreme Court could rule differently this time because of key differences in standing.

This post was originally published on the Cardozo Journal of Equal Rights and Social Justice website on February 26, 2026. The original post can be accessed via the Archived Link button above.

Share

COinS